Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Stephen, Strugnell"'
Autor:
Michael J. Germain, Subir K. Paul, George Fadda, Varshasb Broumand, Andy Nguyen, November H. McGarvey, Matthew D. Gitlin, Charles W. Bishop, Philipp Csomor, Stephen Strugnell, Akhtar Ashfaq
Publikováno v:
BMC Nephrology, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Introduction Extended-release calcifediol (ERC), active vitamin D hormones and analogs (AVD) and nutritional vitamin D (NVD) are commonly used therapies for treating secondary hyperparathyroidism (SHPT) in adults with stage 3–4 chronic kid
Externí odkaz:
https://doaj.org/article/ea5d7f0a4e0d41f78b22eb2bdd5d89d2
Publikováno v:
Journal of the Endocrine Society. 6:A149-A149
Background Extended-release calcifediol (ERC) has been shown in randomized clinical trials to effectively and safely treat secondary hyperparathyroidism (SHPT) in adults with stage 3-4 chronic kidney disease (CKD) and vitamin D insufficiency when adm
Publikováno v:
Nephrology Dialysis Transplantation. 34
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1761:221-234
While current dogma argues that vitamin D prodrugs require side-chain activation by liver enzymes, recent data suggest that hydroxylation may also occur extrahepatically. We used keratinocytes and recombinant human enzyme to test if the 25-hydroxyvit
Publikováno v:
Nephrology Dialysis Transplantation. 21:644-650
BACKGROUND: Active vitamin D compounds are widely used in the treatment of secondary hyperparathyroidism associated with renal failure. These compounds reduce PTH secretion through vitamin D receptor (VDR)-dependent repression of PTH gene transcripti
Publikováno v:
Biochemical Pharmacology. 68:1289-1296
The active vitamin D compound 1alpha,24(S)-dihydroxyvitamin D(2) (1,24(OH)(2)D(2)) is under development as a therapy for disorders including cancer and secondary hyperparathyroidism. 1,24(OH)(2)D(2) is a potent inhibitor of cell proliferation in vitr
Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation
Autor:
Samir P. Tabash, Charles W. Bishop, Jay A. White, Joel Z. Melnick, Stephen Strugnell, Martin Petkovich
Publikováno v:
The Journal of steroid biochemistry and molecular biology. 148
Vitamin D insufficiency is prevalent in chronic kidney disease (CKD) and associated with secondary hyperparathyroidism (SHPT) and increased risk of bone and vascular disease. Unfortunately, supplementation of stage 3 or 4 CKD patients with currently
Publikováno v:
Physiological Reviews. 78:1193-1231
Jones, Glenville, Stephen A. Strugnell, and Hector F. DeLuca. Current Understanding of the Molecular Actions of Vitamin D. Physiol. Rev. 78: 1193–1231, 1998. — The important reactions that occur to the vitamin D molecule and the important reactio
Autor:
J C Knutson, R M Moriarty, C W Bishop, L W LeVan, Stephen Strugnell, R Gilardi, Glenville Jones, Valarie Byford, Hugh L.J. Makin
Publikováno v:
Biochemical Journal. 310:233-241
A major metabolite of the vitamin D analogue 1 alpha-hydroxyvitamin D2 in human liver cells in culture has been identified as 1 alpha,24(S)-dihydroxyvitamin D2 [1 alpha,24(S)-(OH)2D2]. 1 alpha-Hydroxyvitamin D3 incubated with the same cells gives ris
Publikováno v:
Tetrahedron. 49:739-746
Alkylation of the lithio-demethylseleno-derivative of seleno-acetal 11 with chloromethyl isopropyl ether [shown by NMR to give the (22 S )-methylseleno-compound 13a as the major diastereoisomer] is the key reaction in the synthesis of the 24-oxa anal